Aceragen Announces Acquisition of Arrevus, Expands Late-Stage Rare Disease Pipeline

Combination advances strategy of building multi-product commercial rare disease company Portfolio to address Farber disease, Cystic Fibrosis, and Orphan Infectious Diseases RALEIGH-DURHAM, NC – October 28, 2021 – Aceragen, Inc., a biopharmaceutical company focused on advancing transformational therapeutics for rare and orphan diseases, today announced the acquisition of Arrevus, Inc., a clinical-stage biopharmaceutical company developing

Focused On Rare Illnesses, North Carolina Startup Aceragen Goes After Farber Disease

A new North Carolina-based biopharmaceutical company with a focus on rare illnesses hopes to be the first to find a treatment for Farber disease. This extremely rare genetic disorder results in the buildup of a material in the body called ceramide that can inflame and damage many different tissues. Joints, connective tissue, the lungs and